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a  b  s  t  r  a  c  t
High-risk  human  papillomaviruses  (hrHPV)  cause  anogenital  and  oropharyngeal  cancers.  HPV-16/18
virus-like  particle  vaccine  formulated  with  an  AS04 adjuvant  is  very  efﬁcacious  against  hrHPV associated
precancers  but  the  herd  effects  of different  vaccination  scenarios  are  not  known.  Our  cluster randomized
trial  (NCT00534638)  assesses  the  overall  and herd  effects  of vaccinating  girls  vs.  girls and  boys.  In  two
school-years  (2007–2008  and  2008–2009)  we  invited  80,272  1992–1995  born  early  adolescents  to  a  CRT
in 33  communities  a  priori  stratiﬁed  by  low,  intermediate  and high  HPV-16/18  seroprevalence.  In 11 Arm
A communities  90%  of  participating  girls  and  boys  were  assigned  to  receive  HPV-16/18  vaccine,  in 11 Arm
B communities  90%  of girls  were  assigned  to receive  HPV-16/18  vaccine  –  boys  were  assigned  to receive
hepatitis  B-virus  (HBV)  vaccine,  and  in  11  Arm  C  communities  all  were  assigned  to  receive  HBV-vaccine.
Prevalence  of  HPV  in vaccinated  and  unvaccinated  girls  is studied  at  age  18.5  years.  Recruitment  resulted
in equal  enrolment  of four  birth  cohorts  (born  1992–1995)  comprising  altogether  32,175  (40% response)
early adolescents:  20,514  girls  (50.5–53.0%  response  by  arm)  and  11,661  boys  (21.9–31.6%%  response  by
arm).  At  the  age  of  15 years,  79.3%  of the  vaccinees  completed  a questionnaire.  Among  them  >98%  were
living  at, and  during  the  week-ends  1.3–1.6%  stayed  outside,  the study  site communities.  Smoking  habit
and  alcohol  consumption  were  similar  in  the  different  trial  arms,  also mean-age  of menarche  (12.4  years)
and  1st  ejaculation  (12.6  years),  and  sexual  behaviour  (among  those  <25%,  who  had  had  sexual  debut)
did  not  differ  by  arm:  mean-age  at the sexual  debut  14.3  and  14.4  in  girls  and  boys,  and  proportions  of
those  with  multiple  (≥5)  life-time  sexual  partners  (6.5–7.5%)  at the  age  of  15  years.  Uniform  residential,
life-style  and  sexual  behaviour  characteristics  indicate  successful  randomization/enrolment  of  the  CRT.
Our  CRT  will  verify  modelled  predictions  on  up  to  31%  herd  effect  of vaccinating  both  girls  and  boys  with
moderate  vaccine  coverage  – quantifying  overall  effectiveness  of different  strategies  which  will  soon
guide  how  to  implement  HPV  vaccination.
ublis© 2014  The  Authors.  P
. IntroductionVirus-like particle (VLP) vaccines against high-risk human papil-
omavirus (hrHPV) types 16 and 18 (Gardasil® and Cervarix®) have
∗ Corresponding author. Tel.: +358 405437862; fax: +358 3 2100004.
E-mail address: llmale@uta.ﬁ (M.  Lehtinen).
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
been licensed for females in most countries [1–4]. Moderate or
very high vaccine efﬁcacies (VE) against overall cervical intraep-
ithelial neoplasia grade 3 (CIN3), that is, the cervical precancer,
irrespectively of HPV type, have been reported [5], and ongo-
ing Nordic long-term follow-up trials involving more than 22,000
young women  [6,7] will help to deﬁnitively determine whether
the two vaccines are efﬁcacious against invasive cervical cancer.
The two  vaccines have also been highly immunogenic [8,9] and/or
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ccine 33 (2015) 1284–1290 1285
e
n
m
v
d
E
r
t
b
d
c
[
p
d
[
N
p
o
a
v
c
C
2
2
m
o
o
v
t
r
a
M
s
h
d
s
(
w
c
C
c
m
2
w
t
5
o
s
o
V
r
t
P
D
t
Fig. 1. Human papillomavirus (HPV) type-16/18 seroprevalence (%) among <23 year
old Finnish women  in 2006/7 (study site communities are circled by vaccinationM. Lehtinen et al. / Va
fﬁcacious in males [9] leading to implementation of male vacci-
ation by a few health authorities [10,11].
Female HPV vaccination programmes have been launched in
any countries [12,13] but even if highly efﬁcacious at the indi-
idual level low vaccination coverage threatens herd effect and the
esired public health impact [12–14]. In the US and continental
urope devoid of school-based vaccination programmes, free indi-
ect protection due to herd effect will probably remain low since
he coverage of HPV vaccination in the females has mostly been
etween 30% and 50%, with moderate compliance in receiving three
oses [12,15,16] Coverage of even the best school-based HPV vac-
ination programmes among girls has been in the range of 70–90%
13,17–19] leaving a proportion of (marginalized) girls without
rotection [20]. Modelling suggest increased effectiveness by gen-
er neutral vaccination programmes which are gaining attention
21,22].
Our cluster randomized trial (CRT:ClinicalTrials.gov reg.number
CT00534638) aims to identify the most effective HPV vaccination
rogramme among various modelled programmes for 12–15 year
ld early adolescents by assessing overall and indirect effectiveness
nd safety of the two major HPV vaccination strategies; that is, to
accinate early adolescents girls only, or to vaccinate early adoles-
ent girls and boys. We  present here the key characteristics of our
RT.
. Methods
.1. Stratiﬁed randomization of study site communities
There are 57 communities in Finland, outside the Helsinki
etropolitan area, with more than 35,000 inhabitants. The number
f eligible communities was 34 based on a 50 km distance cut-
ff (25 km in southern Finland) between communities. To control
ariation of background HPV exposure rates in the 33 communi-
ies (one was excluded) we determined HPV-16/18 seroprevalence
ates in 50 per community under age 23 years in 1983–2003 [23,24]
nd 2006 using serum samples from the population-based Finnish
aternity Cohort (FMC). The serum bank stores ﬁrst trimester
erum samples from 98% of pregnant Finnish women, all of whom
ave given informed consent for medical research [22]. Before ran-
omization into the three study arms the 33 communities were
tratiﬁed into three groups according to low (<20.5%), intermediate
20.5–24%) and high (>24%) of HPV-16/18 seroprevalence (Fig. 1),
hich resulted in a low coefﬁcient of variation (CV) of 0.13 across
ommunities, and ample power for the study with a conservative
V estimate of 0.15 and reasonable sample size, i.e. numbers of
ommunities per study arm for the overall effectiveness assess-
ent (Table 1).
.2. Enrolment and follow-up
Ethical clearance for this investigator initiated [25,26] trial
as obtained in June 2007 from the Ethical Review Board of
he Pirkanmaa Hospital District (Eudra-CT number 2007-001731-
5). Identiﬁcation of residents 1992–1995 born and their parents
r legal guardians in the 33 communities was based on per-
onal identity codes (PIC) and the Population Register Centre
f Finland. Informed consent based linkages of the Registry of
accinated Individuals (RVI) and two population-based health
egistries: the Hospital Discharge Registry (HILMO [27]) and
he Finnish Cancer Registry (FCR [28]) will utilize this unique
IC (Finnish National Institute for Health & Welfare permission,
nro 33/5.05.00/2009).
All the 80,272 Finnish or Swedish speaking boys and girls in
he 1992–1995 birth cohorts were invited during two school yearsstrategy: (A) HPV vaccination of boys and girls, black circle. (B) HPV vaccination of
girls only, boys were assigned to receive hepatitis B-virus (HBV) vaccine, grey circle.
(C)  HBV vaccination of boys and girls, white circle.
(2007–2008 and 2008–2009) by letters sent to their parents or
legal guardians (preferably mother) living in the same household.
The letters included pertinent study information, consent form
and a prepaid envelope for the consent. Six thousand 1992–1995
born immigrants whose native language was neither Finnish nor
Swedish were also eligible to participate in the study (translation
provided when needed) although not invited by letters
After receiving the parental informed consent, the study nurses
arranged the ﬁrst appointment at school health care facilities of
the 250 municipal junior high schools the students were attend-
ing. Following informed consent 90% of the participating girls and
boys were assigned to receive Cervarix® (referred hereafter as HPV-
16/18) -vaccine and 10% were assigned to receive EngerixTM B
(referred hereafter as hepatitis B-virus, HBV) -vaccine in 11 Arm A
communities, 90% of the girls were assigned to receive Cervarix®-
vaccine, 10% of girls were assigned to receive HBV-vaccine and
all boys received HBV-vaccine in 11 Arm B communities, and all
participants were assigned to receive HBV-vaccine in 11 Arm C
communities. The next two vaccine doses (at months 1 and 6) were
given at schools by the same study nurses. Blinding was maintained
for all subjects in arm A and for girls in arm B. During the immu-
nization phase serious adverse effects (SAE) were surveyed and
reported for 12 months.
At the age of 15 years both girls and boys received a ques-
tionnaire on living conditions, life habits and sexual behaviour. In
addition, all female study participants and all Finnish or Swedish
1286 M. Lehtinen et al. / Vaccine 3
Table 1
Number of communities needed to have at least 90% of power at ﬁnal analysis for
the  co-primary objectives (testing at age 18.5, community size 1000) assuming a
0.15 co-efﬁcient of variation in background HPV16/18 exposure by community, and
no  change in sexual activity in Arms A (90% of boys and girls assigned to receive
HPV  vaccination, B (90% of girls assigned to receive HPV vaccination, boys assigned
to  receive hepatitis B-virus, HBV vaccination, and C (both boys and girls assigned to
receive HBV vaccination) during the trial.
Coverage Comparison Number of
communities
55% A vs. C 3.8 (3.1–5.1)*
B vs. C 5.3 (3.7–9.9)*
50% A vs. C 4.1 (3.3–6.0)*
B vs. C 6.0 (4.0–13.3)*
45% A vs. C 4.7 (3.5–7.5)*
B vs. C 7.1 (4.2–19.2)*
40% A vs. C 5.3 (3.7–10.0)*
B vs. C 8.4 (4.5–31.0)*
35% A vs. C 6.3 (4.0–14.7)*
B vs. C 10.4 (4.9–60.4)*
30% A vs. C 7.8 (4.4–25.3)*
B vs. C 13.5 (5.4–170.3)*
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uNumber of communities needed when the effect of the trial is increased or
ecreased by 20% (20% more or 20% fewer cases prevented by HPV vaccination than
he model predicts).
peaking female residents of the study site communities born
etween 1992 and 1995 were invited at the age of 18.5 years
o attend a follow-up visit to obtain a cervical sample (and for
he 1994 and 1995 birth cohorts an oral gargle sample) taken
y a study nurse, and a self-collected cervico-vaginal sample for
PV and/or Chlamydia trachomatis PCR analyses. In addition, the
emale study participants were offered the vaccine (either HBV-
accine or HPV-16/18 -vaccine) they had not received at the junior
igh-school.
.3. Statistical analyses
Descriptive statistics of the participants by arm were performed
or the 1992–1995 born study participants living in the study site
ommunities and answering the questionnaire at the age of 15
ears.
Two separate dynamic transmission models [21,22,29] cali-
rated to Finnish data were used for the estimation of herd effect
the relative reduction of HPV prevalence among unvaccinated girls
ompared to no-HPV-16/18 vaccination scenario, Arm C) by the
RT-speciﬁc HPV-16/18 vaccine coverages among girls in Arm B
nd girls and boys in Arm A assuming 95% vaccine efﬁcacy against
PV-16/18 infection, and 4.6% or 8.3% prevalence rate of HPV-16/18
nfection in unvaccinated 18.5-year old females.
. Results
.1. Enrolment
During 2007–2009 two invitation letters were sent to the par-
nts of 39,420 girls and 40,852 boys. The median numbers of invited
irls and boys by community were: 1018 (range 482–3809), and
110 (range 496–3920), respectively. Invitation letters to those
orn 1992–1993 were sent starting in October 2007, to those born
994 in August 2008 and to those born 1995 in October 2008.
hereafter, study nurses in the 33 study site communities gave
ral presentations at 250 junior high-schools involving the 9th and
th grade classes (15- to 13-year olds, school year 2007–2008)
nd the 8th and 7th grade classes (14- to 12-year olds, school
ear 2008–2009), as well as at parents’ evenings organized by
he schools. The numbers of volunteers and vaccinated individ-
als increased rapidly during both school years in Autumn 20073 (2015) 1284–1290
and 2008, reaching a plateau by the end of April 2008 and 2009
(Fig. 2).
Overall, the numbers of enrolled subjects and the proportions
of the invited subjects (11,661, 28.5% of boys and 20,514, 52.0% of
girls) were equally distributed between the study arms (Table 2).
The proportions of vaccinated boys, however, increased in all study
arms by approximately 5 percentage points during the enrolment
phase (20.5%, 1992 vs. 24.8%, 1995, Arm A, and 29.8% and 27.5%,
1992 vs. 33.6% and 34.6%, 1995, Arms B and C, respectively). The
female participation rates were materially equal in all the study
arms: Arm A) 52.8%, Arm B) 50.5%, and Arm C) 53.0% (Table 2).
The proportions of HPV-16/18 vaccinated girls were not remarkably
different in arms A and B (approximately 47.5% vs. 45.5%). In Arms
A and B there were no outlier communities having more than a 15
per cent difference from the average vaccine coverage. In Arm C,
two communities had over 70% vaccine coverage in girls.
3.2. Residential history and life-style characteristics
At the age of 1598.5%, 98.2% and 98.3% of the study participants
were living at the A, B and C study site communities (Table 3). Dur-
ing the week-ends 1.4%, 1.2% and 1.4% of the study participants
stayed usually outside the A, B and C communities, respectively.
Also smoking habit and alcohol consumption were similar in the
trial arms, and there were no major differences between male
and female study participants: neither for never smokers (range
66.4–70.2%) vs. current smokers (range 16.7–19.0%), nor for never
consumers (range 45.2–51.8%) vs. once or twice a week alcohol con-
sumers (range 1.7–2.4%) (Table 4). However, heavy smoking was
twice as common in boys than in girls.
3.3. Sexual behaviour characteristics
The characteristics of sexual development (menarche, mean-
age 12.4 years/1st ejaculation, mean-age 12.6 years) did not differ
by trial arm (Table 5). Also sexual behaviour, mean age at sex-
ual debut (among those approximately 21% and 24% of boys and
girls, who had had their 1st sexual intercourse) were similar;
that is, mean-age 14.4. years (boys) and mean-age 14.3 years
(girls) (Table 4). Among those who  had had their 1st sexual inter-
course by 15 years, the numbers of (multiple ≥5) life-time sexual
partners were similar by study arm and gender (range 6.5–7.5%)
(Table 5).
3.4. Predicted herd effects
Finally, two established dynamic transmission models were
used to predict herd effect for the different HPV vaccination strate-
gies using the vaccine coverage rates observed. While in the Arm
B (girls only) communities the predicted herd effects were low,
in the Arm A (girls and boys) communities with approximately
47.5% and 19.8% HPV-16/18 vaccine coverage rates, respectively,
the predicted herd effects on HPV-16 prevalence ranged between
14% and 31% among the 1994-born and 1995-born unvaccinated
18.5 year-old girls (Table 6).
4. Discussion
We  enrolled early adolescent girls and boys to a population-
based, cluster randomized trial on the effectiveness of different
HPV vaccination strategies with on average 45.5–47.5% HPV-16/18
vaccine coverage in the females, and 19.8% coverage in the males.
According to established dynamic transmission models [21,22]
this will yield eventually up to 17–31% herd effect. Randomiza-
tion of the study site communities was successful in yielding
M. Lehtinen et al. / Vaccine 33 (2015) 1284–1290 1287
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Hig. 2. Cumulative numbers of HPV-16/18 vaccinated and non-HPV-16/18 vaccin
1992–1993 born) and 2008–2009 (1994–1995 born) at the 33 study sites. The x-a
ay  2009 (the y-axis indicates the number of volunteers (blue columns) and vaccin
niform residential, demographic, life-style and sexual behaviour
articipant characteristics for the trial arms.
The enrolment took place over two school years with constant
ace the 1992–1993 and 1994–1995 birth cohorts attending during
he ﬁrst halves of two consecutive school-years 2007–2008 and
able 2
umber (%) recruited/invited (80,272) 1992–1995 born girls and boys by vaccine arm* an
Arm 1992 1993 1994 
N n % N n % N 
A Girls 3143 1545 49.2 3191 1621 50.8 3063 
Boys  3246 666 20.5 3230 617 19.1 3066 
B  Girls 3844 1940 50.5 3746 1846 49.3 3572 
Boys  4132 1232 29.8 3934 1237 31.4 3756 
C  Girls 3398 1752 51.6 3142 1553 49.4 3040 
Boys  3349 922 27.5 3286 946 28.8 3118 
Total  Girls 10,385 5237 50.4 10,079 5020 49.8 9675 
Boys  10,727 2820 26.3 10,450 2800 26.8 9940 
 = Number of invited subjects; n = Number of recruited subjects; % = n/N.
* (A) 90% of girls and boys received human papillomavirus (HPV)-16/18 vaccine, 10% g
PV-16/18 vaccine, 10% of girls and 100% boys received the HBV vaccine. (C) 100% of girl
# Q1/2010, for the 1995 birth cohort1992–1995 born adolescents attending the trial in two school years 2007–2008
icates school weeks starting from October 2007 to May  2008, and August 2008 to
range column).
2008–2009, respectively. We had only a few outlier communities.
Two Arm C communities had over 70% vaccination coverage but
this does not have an effect on the herd effect estimates, since only
HBV vaccine was  used in these communities. There was only a small
difference in the participation rate of adolescent girls between Arm
d birth cohort in 2007–2008 and 2008–2009(10)#.
1995 1992–1995
n % N n % N n %
1772 57.9 2846 1530 53.8 12,243 6468 52.8
726 23.7 2921 725 24.8 12,463 2734 21.9
1853 51.9 3408 1725 50.6 14,570 7364 50.5
1194 31.8 3638 1222 33.6 15,460 4885 31.6
1734 57.0 3027 1643 54.3 12,607 6682 53.0
1075 34.5 3176 1099 34.6 12,929 4042 31.3
5359 55.4 9281 4898 52.8 39,420 20,514 52.0
2995 30.1 9735 3046 31.3 40,852 11,661 28.5
irls and boys received hepatitis B-virus (HBV) vaccine. (B) 90% of girls received the
s and boys received the HBV vaccine.
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Table 3
Residential (upper part) and week-end (lower part) histories of the HPV vaccine trial participants at junior high school at the age of 15 years by gender and trial arm.
Category Arm A Arm B Arm C
Boys Girls Boys Girls Boys Girls
N  = 2059 N = 5154 N = 3751 N = 6017 N = 3089 N = 5459
n  (%) n (%) n (%) n (%) n (%) n (%)
Lived in the same community
where attending school
2019(98.3) 5076(98.7) 3667(98.2) 5893(98.1) 3027(98.4) 5344(98.2)
Lived  in another community at
baseline
35(1.7) 68(1.3) 68(1.8) 114(1.9) 49(1.6) 97(1.8)
Missing 5(−) 10(−) 16(−) 10(−) 13(−) 18(−.)
Stayed in the community where
was  living
1378(67.5) 3408(66.7) 2561(68.6) 4109(68.8) 2071(67.5) 3666(67.6)
Stayed  occasionally in another
community
637(31.2) 1631(31.9) 1121(30.0) 1794(30.1) 949(30.9) 1687(31.1)
Stays usually in another
community
27(1.3) 70(1.4) 49(1.3) 67(1.1) 50(1.6) 69(1.3)
Missing 17(−) 45(−) 20(−) 47(−) 19(−) 37(−)
N = number of subjects; n (%) = number (percentage) of subjects in a given category.
Table 4
Smoking and drinking habits of the HPV vaccine trial participants at junior high school at the age of 15 years by gender and trial arm.
Category Arm A Arm B Arm C
Boys Girls Boys Girls Boys Girls
N  = 2059 N = 5154 N = 3751 N = 6017 N = 3089 N = 5459
n  (%) n (%) n (%) n (%) n (%) n (%)
Never smoked 1339(69.3) 3196(66.4) 2441(69.7) 3919(70.0) 2071(70.2) 3458(68.2)
Quitted smoking 264(13.7) 705(14.6) 477(13.6) 750(13.4) 372(12.6) 739(14.6)
Current smokers 330(17.1) 914(19.0) 583(16.7) 933(16.7) 509(17.2) 873(17.2)
Missing 126(−) 339(−) 250(−) 415(−) 137(−) 389(−)
≤One  pack a month 173(33.9) 540(37.4) 313(33.6) 598(40.2) 243(31.3) 618(43.7)
Two  packs a month 45(8.8) 173(12.0) 110(11.8) 208(14.0) 89(11.5) 163(11.5)
One  pack a week 73(14.3) 247(17.1) 126(13.5) 276(18.6) 119(15.3) 219(15.5)
Two  packs a week 68(13.3) 233(16.2) 132(14.2) 185(12.4) 112(14.4) 178(12.6)
Half  a pack a day 123(24.1) 213(14.8) 207(22.2) 178(12.0) 157(20.2) 199(14.1)
≥One pack a day 28(5.5) 36(2.5) 43(4.6) 41(2.8) 57(7.3) 36(2.5)
Missing 1549(−) 3712(−) 2820(−) 4531(−) 2312(−) 4046(−)
Did  not consume 956(49.6) 2169(45.2) 1778(50.7) 2607(46.7) 1530(51.8) 2399(47.6)
≤once a month 667(34.6) 1812(37.7) 1189(33.9) 2065(37.0) 958(32.4) 1852(36.8)
2–4  times a month 253(13.1) 715(14.9) 467(13.3) 777(13.9) 395(13.4) 696(13.8)
68
4
245
A
i
a
s
T
S1–2  times a week 46(2.4) 103(2.1) 
≥3  times a week 6(0.3) 4(0.1) 
Missing 131(−) 351(−) 
 and Arm B which resulted in a negligible (two percent) difference
n the HPV-16/18 vaccine coverage rates in girls between the two
rms.
The trial enrolment of early adolescent boys was not particularly
uccessful in the Arm A communities, where the HPV-16/18 vaccine
able 5
exual development and sexual behaviour of the HPV vaccine trial participants at junior 
Category Arm A 
Boys Girls
N  = 2059 N = 5
n  (age or %) n (ag
Mean age (years) at 1st ejaculation/menarche 1492(12.6) 4418
Missing 567 736
Sexual debut by 15 years of age 435(21.8%) 1283
Mean  age (years) at sexual debut 410(14.4) 1202
Number of sex partners* by 15 years of age 1 255(58.9%) 707
2  90(20.8%) 276
3–4  59(13.6%) 212
≥5  29(6.7%) 88
Missing 1626 3871
* Calculated for those study participants who had had the ﬁrst sexual intercourse by ag(1.9) 128(2.3) 64(2.2) 88(1.7)
(0.1) 3(0.1) 6(0.2) 3(0.1)
(−) 437(−) 136(−) 421(−)
was offered also to boys, probably due to the fact that parental and
minor informed consents were both required. Active recruitment
and the information package provided at the junior high schools
increased the participation in the Arm A communities from 19.1%
(1993-born) to 24.8% (1995-born) during the two school years. Such
high school at the age of 15 years by gender and trial arm.
Arm B Arm C
 Boys Girls Boys Girls
154 N = 3751 N = 6017 N = 3089 N = 5459
e or %) n (age or %) n (age or %) n (age or %) n (age or %)
(12.4) 2657(12.6) 5176(12.5) 2237(12.6) 4685(12.4)
 1094 841 852 774
(25.3%) 732(20.1%) 1419(24.0%) 605(20.2%) 1262(23.5%)
(14.3) 687(14.3) 1315(14.3) 577(14.4) 1162(14.3)
(55.1%) 414(56.9%) 766(54.1%) 344(57.0%) 684(54.3%)
(21.5%) 160(22.0%) 294(20.8%) 142(23.5%) 276(21.9%)
(16.5%) 107(14.7%) 256(18.1%) 76(12.6%) 204(16.2%)
(6.9%) 47(6.5%) 99(7.0%) 41(6.8%) 95(7.5%)
 3023 4602 2486 4200
e of 15 years.
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Table  6
Modelled* reduction of HPV16 prevalence in unvaccinated 18.5-year old females following vaccination of 1992–1995 –born birth cohorts (BC) in 2007–2010 (at 12 to 15
years  of age) by different vaccination strategies and vaccine coverages.
Birth cohort/Calendar year ICL/IARC modela THL/UTA modelb
BC-92/2011 BC-93/2012 BC-94/2013 BC-95/2014 BC-92/2011 BC-93/2012 BC-94/2013 BC-95/2014
Vaccine coverage♀ 45.5% (Arm B)
Prevalence n.a. 4.0% 3.6% 3.5% 8.2% 8.0% 7.9% 7.7%
Reduction n.a. 15% 22% 24% 1.8% 3.5% 5.5% 7.4%
♀ 47.5%/♂ 19.8% (Arm A)
Prevalence n.a. 3.7% 3.2% 3.2% 7.8% 7.5% 7.2% 6.9%
Reduction n.a. 22% 30% 31% 6.5% 10% 14% 17%
n
ata fr
w
p
e
p
H
s
c
n
h
i
l
w
N
c
1
p
n
b
n
H
y
i
s
s
t
f
o
t
T
d
g
e
i
o
U
t
r
u
o
h
C
i
a
o
d
c
c
p.a. = not available.
* Dynamic transmission model [21,22] predicted herd-effect to be veriﬁed with d
omen: 4.6%a and 8.3%b.
henomenon was also seen in the Arm B and C communities. Math-
matical models suggest that HPV vaccination of both boys and girls
rovides a strong herd effect [21,22,29] and can substitute for low
PV vaccine coverage in the females [21]. In the upcoming analy-
es it will be useful to assess the effectiveness estimates by birth
ohort since both the absolute numbers and proportions of vacci-
ated males are the highest in the youngest birth cohorts, which
ave on top 2–3 vaccinated birth cohorts, predicted to translate
nto stronger herd effects.
Strengths of our study are uniform enrolment of the early ado-
escents by school year and birth cohort and community. There
as no confounding by opportunistic or national HPV vaccination.
otably homogeneous participation of both vaccinated and unvac-
inated 18.5 year-old girls (approximately 3000 by birth cohorts
992–1995, data not shown) to cervical sampling at the follow-up
hase is important for the assessment of the overall effective-
ess and the herd effect. No differences existed in the sexual risk
ehaviour characteristics by study community or arm. It is also
oteworthy, that the recently (November 2013) launched national
PV vaccination programme in Finland involving 1998-born and
ounger girls will not interfere with the herd effect estimation even
n the last birth cohort (born 1995).
At the baseline there was very little daily/weekly mobility out-
ide the study site communities. The demographics, life-style and
exual behaviour characteristics of the study participants indicate
hat both the randomization and study enrolment were success-
ul. A similar more detailed questionnaire to be fulﬁlled at the end
f the study by the 18.5 year-old girls and boys will provide fur-
her assurance on the comparability of the study site communities.
he Finnish population is genetically homogeneous although some
ifferences in the distribution of cervical cancer associated HLA
enes (DR2 and B15) have been reported [30]. There, however, are
qual numbers of Swedish speaking participants in one community
ncluded in each of the arms A, B and C.
Finally, the overall vaccination coverages among females meets
r exceeds many of the national vaccination programmes in the
S and Europe and over some Australian counties in which only
he school-based system has provided more than 70% coverage
ates [12,13,15–18]. With the more than 12,000 vaccinated and
nvaccinated 18.5 year-old girls now sampled, the amply powered
verall effectiveness data, and the unique randomized-trial based
erd effect data by different vaccination strategies provided by our
RT will be critical for evidence-based decision making especially
n poor resource countries. Also comparison of the study arms A
nd B in relation to the direct assessment of overall effectiveness
f vaccinating girls only or girls and boys will be important. This
ata is needed to overcome the emergence of new HPV associated
ancer epidemics in both males and females [31,32] which low
overage in girls only probably cannot tackle. Extensive cross-
rotection by the current HPV-16/18 vaccine [33] and the newom the community randomize trial, assumed baseline prevalence in unvaccinated
multivalent HPV vaccines further emphasize the need to identify
the HPV vaccination strategy needed for elimination(eradication)
of the major hrHPV types [5].
In conclusion the randomization and enrolment in our
community-randomized effectiveness trial have been successful.
We will have a sound basis for estimating the overall effectiveness
and indirect herd effect of the different HPV vaccination strategies
to reduce cervical HPV prevalence in adolescent women. Evidence-
based decision making will follow.
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